Karyopharm Therapeutics Inc.

KPTI

Held by 2 specialist biotech funds

2 funds opened new positions. Next phase3 readout (Selinexor): Feb 2026. Short interest: 26.8% of float.

BiotechnologyCEO: Richard A. PaulsonIPO: 2013Website ↗

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

Catalysts

Phase 2Q2 2015SelinexorDiabetic Foot UlcersNCT02367690

Primary: Presence of Local Skin Reactions (LSR) (84 days)0Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 2NegativeQ4 2015Selinexor (KPT-330)Squamous Cell CarcinomaNCT02213133

Primary: Percentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (up to 14.6 months)Enrollment:45/45Sites: 18NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ1 2016SelinexorPeripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)NCT02314247

Primary: Overall Response Rate (ORR) (Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.)Enrollment:16/16Sites: 5NA, TREATMENT

Phase 2NegativeQ2 2016SelinexorProstate CancerNCT02146833

Primary: Percentage of Participants With Overall Clinical Benefit Response (CBR) (At 12 weeks)Enrollment:20/20Sites: 1RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2016selinexorRichter's TransformationNCT02138786

Primary: Percentage of Participants With Overall Response (Overall Response Rate) (Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.)Enrollment:27/27Sites: 17NA, TREATMENT

Phase 2PositiveQ1 2017SelinexorOvarian Carcinoma, Endometrial Carcinoma, Cervical CarcinomaNCT02025985

Primary: Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) (Baseline up to 30 days after last dose administration, assessed after 6 weeks and 12 weeks (approximately 35 months))Enrollment:116/116Sites: 4RANDOMIZED, TREATMENT

Phase 2Q2 2017SelinexorMultiple MyelomaNCT02628704

Primary: Progression Free Survival (PFS) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months)0Sites: 2RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2017SelinexorMyelodysplastic SyndromeNCT02431351

Primary: Hematologic improvement (based on the 2006 International Working Group (IWG) response criteria) (6 months)0NA, TREATMENT

Phase 2PositiveQ1 2018SelinexorAcute Myeloid Leukemia (AML)NCT02088541

Primary: Overall Survival (Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks))Enrollment:317/317Sites: 78RANDOMIZED, TREATMENT

Phase 2Q1 2018SelinexorMultiple MyelomaNCT02389543

Primary: Determine maximum tolerated dose (MTD) (12 months)0RANDOMIZED, TREATMENT

Phase 2PositiveQ3 2019SelinexorMultiple MyelomaNCT02336815

Primary: Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC) (Baseline until disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 17 months))Enrollment:202/202Sites: 61NON_RANDOMIZED, TREATMENT

Phase 2Q3 2020SelinexorCoronavirus InfectionNCT04355676

Primary: Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale (Baseline to Day 14)0RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2020SelinexorCoronavirus InfectionNCT04349098

Primary: Percentage of Participants With At-least a 2-Point Improvement in Ordinal Scale (Baseline up to Day 14)Enrollment:190/190Sites: 33RANDOMIZED, SINGLE, TREATMENT

Phase 3PositiveQ4 2020SelinexorDedifferentiated LiposarcomaNCT02606461

Phase 3Q1 2022SelinexorEndometrial CancerNCT03555422

Primary: Progression Free Survival (PFS) (Time from randomization until disease progression (PD) or death, whichever occurs first (approximately 12 months after the last participant enrolled))Enrollment:263/263Sites: 78RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2023SelinexorGlioblastoma MultiformeNCT04421378

Phase 2NegativeQ3 2023SelinexorLocally Advanced Unresectable or Metastatic MelanomaNCT04768881

Phase 2Q3 2024Selinexor 100 mgNon-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid TumorsNCT04256707

Phase 2Q4 2025SelinexorRelapsed or Refractory Diffuse Large B-Cell LymphomaNCT04607772

Phase 3Q1 2026SelinexorMyelofibrosisNCT04562389

Primary: Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan (At Week 24)Enrollment:353/353Sites: 166RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2026SelinexorEndometrial CancerNCT05611931

Primary: Investigator assessed Progression Free Survival (PFS) per RECIST v1.1 (From randomization until disease progression (PD) or death, whichever occurs first (up to 34 months))Enrollment:257/257Sites: 191RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2026SelinexorMyelofibrosisNCT04562870

Primary: Percentage of Participants with Spleen Volume Reduction of Greater Than or Equal to (≥) 35 Percent (%) (SVR35) (From Baseline up to Week 24)Enrollment:Target 112Sites: 21RANDOMIZED, TREATMENT

Phase 3Q4 2026Selinexor (combination therapy)Relapsed/Refractory Diffuse Large B-cell LymphomaNCT04442022

Primary: Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014 (From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization))Enrollment:Target 501Sites: 38RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2026SelinexorDiffuse Large B-cell LymphomaNCT02227251

Primary: Part 1: Overall Response Rate (ORR) (One year)Enrollment:Target 244Sites: 175RANDOMIZED, TREATMENT

Phase 2Q2 2027SelinexorMultiple MyelomaNCT02343042

Primary: Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD) (12 months)Enrollment:Target 300Sites: 25RANDOMIZED, TREATMENT

Phase 2Q2 2027Selinexor 60 mgMyelofibrosis, Moderate Thrombocytopenia, Mild ThrombocytopeniaNCT05980806

Phase 2Q1 2028SelinexorMultiple Myeloma, RefractoryNCT04414475

Recent News & Research

PubMed

Incorporation of selinexor into conditioning regimens prior to allogeneic hematopoietic stem cell transplantation: a single-center clinical study.

# Investment Summary: Selinexor in HSCT Conditioning This study evaluates selinexor (KPTI's lead XPO1 inhibitor) as part of pre-transplant conditioning regimens for allogeneic hematopoietic stem cell transplantation, potentially expanding its addressable market beyond multiple myeloma and lymphoma into the transplant setting. Positive efficacy and safety data could strengthen KPTI's clinical pipeline and support label expansion arguments to payers, though the competitive landscape for conditioning regimens is established and adoption would depend on demonstrating clear survival or toxicity advantages over standard-of-care approaches. The commercial impact remains uncertain without comparison to control arms and longer-term outcome data, but successful development could unlock a new revenue stream in hematologic malignancies.

Dec 31, 2026

PubMed

Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study.

# Investment Summary: KPTI Selinexor in High-Risk Multiple Myeloma This prospective observational study demonstrates selinexor (KPTI's XPO1 inhibitor) combined with standard-of-care triplet therapy (bortezomib, lenalidomide, dexamethasone) in newly diagnosed high-risk multiple myeloma patients, addressing a patient population with limited treatment options and poor prognosis. If efficacy and safety data support approval or expanded labeling, this could broaden selinexor's addressable market in the first-line setting, potentially capturing additional market share in the estimated 50,000+ annual U.S. MM diagnoses where ~15-20% carry high-risk features. The clinical validation in this high-risk subset is commercially meaningful because these patients typically have shorter overall survival and would support premium pricing and differentiated positioning versus mono-therapy

Dec 1, 2026

PubMed

Selinexor potentiates NK cell activation against multiple myeloma.

# Investment Summary: Selinexor + NK Cell Activation in Multiple Myeloma This research demonstrates that selinexor (KPTI's lead XPO1 inhibitor) enhances natural killer cell-mediated immune responses against multiple myeloma, suggesting a potential immunological mechanism complementing its direct anti-cancer activity. The finding could expand selinexor's therapeutic rationale beyond its current approved indications (relapsed/refractory MM and diffuse large B-cell lymphoma) and support combination strategies with NK cell-based therapies or immunomodulatory drugs, potentially strengthening its competitive position in a crowded myeloma market. However, the clinical relevance depends on whether this translates to superior efficacy in ongoing or future trials—the mechanistic discovery alone does not guarantee commercial differentiation without supporting clinical evidence.

Sep 26, 2026

PubMed

Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.

# ALLG MM23 (SeaLAND) Trial Summary for KPTI Investors **Clinical Results:** The phase 3 SeaLAND trial evaluated selinexor (Karyopharm's XPO1 inhibitor) plus lenalidomide versus lenalidomide monotherapy as post-transplant maintenance in newly diagnosed multiple myeloma, establishing efficacy data in a standard-of-care comparison setting. **Investment Implications:** A positive readout would support selinexor's expansion into the high-volume maintenance therapy segment—a significant commercial opportunity given the routine use of post-transplant maintenance in newly diagnosed myeloma. However, results will likely depend on progression-free survival improvements versus the established lenalidomide backbone and tolerability profile, which will determine whether selinexor gains adoption in this maintenance setting where treatment burden and toxicity directly impact market penetration and reimb

Sep 22, 2026

PubMed

CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8(+) T cells.

# Investment Summary: KPTI CD73 Inhibitor Combination Study **Clinical Significance:** This preclinical research demonstrates that combining a CD73 inhibitor with selinexor (KPTI's approved XPO1 inhibitor) restores CD8+ T cell activation and enhances anti-tumor activity in multiple myeloma, suggesting a potential combination strategy to overcome immune resistance mechanisms. **Commercial Implication:** If validated in clinical trials, a CD73/selinexor combination could expand selinexor's market applicability and clinical utility in MM, though KPTI would likely need to partner or acquire CD73 inhibitor technology to realize this approach, representing both opportunity and potential dilution/cost considerations for shareholders. --- *Note: This is early-stage preclinical work; clinical proof-of-concept and regulatory pathway clarity would be necessary before assessing true commercial value

Aug 27, 2026

Karyopharm Therapeutics Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research